Roxithromycin Market Revenue Opportunies By Top Players Hetero Healthcare Ltd., Finecure Pharmaceuticals Ltd., Zhejiang Zhenyuan Pharmaceutical Co Ltd, Johnson & Johnson Private Limited, Hygeia Laboratories Inc, Bayer AG, Allergan plc., Galderma S.A, Vale

Increasing research for new applications of roxithromycin is expected to propel growth of the roxithromycin market during the forecast period. For instance, according to a research by Otago University, New Zealand in July 2018, roxithromycin can be effective in treating myeloma, a cancer of plasma cells that usually arises in the bone marrow and is mainly associated with depletion of hemoglobin levels. The drug aids in increasing hemoglobin levels, which strongly suggests that the amount of myeloma in bone marrow has reduced. However, the drug is still under research to confirm its use in treating myeloma.

Download PDF Brochure of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/2257

Roxithromycin Market– Restraint

Drug recalls due to failures in meeting quality standards is expected to hinder growth of the market. For instance, in July 2016, Ministry of Health, Vietnam recalled Rom-150 tablets (Roxithromycin 150mg) manufactured by Zee Laboratories and imported by Codupha Central Pharmaceutical JSC in Vietnam. The decision to recall these drugs was based on tests performed by the National Institute of Drug Quality Control.

Roxithromycin Market– Regional Analysis

On the basis of region, the global roxithromycin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the global roxithromycin market during the forecast period. This is owing to increasing government initiatives to prevent antimicrobial resistance and growing awareness for proper use of antibiotics. For instance in March 2015, Health Canada released Federal Action Plan with rules to reduce the risk of antimicrobial resistance in Canada, which includes infection prevention and control, research and innovation in developing antibiotics, and appropriate antimicrobial use for health professionals and the public of Canada.

Roxithromycin, also known as arrow-roxithromycin, is a semi-synthetic macrolide antibiotic, which prevents bacterial growth by interfering with protein synthesis. The drug is indicated to treat certain types of bacterial infections such as pharyngitis, sinusitis, bronchitis and pneumonia, urinary and soft tissue infections, and otitis media.

Key players operating in the global roxithromycin market include, Hetero Healthcare Ltd., Finecure Pharmaceuticals Ltd., Zhejiang Zhenyuan Pharmaceutical Co Ltd, Johnson & Johnson Private Limited, Hygeia Laboratories Inc, Bayer AG, Allergan plc., Galderma S.A, Valeant Pharmaceutical International, and Stiefel Laboratories

Request For Customization Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-customization/2257

Roxithromycin Market– Taxonomy

By Indication

Urinary and Soft Tissue Infections
Respiratory Tract Infections
Pneumonia
Otitis media
Sinusitis
By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region

North America
Europe
Asia Pacific
Latin America
Middle East
Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.